Highlights:

  • The platform from CytoReason places a high value on accuracy, speed, and safety—all factors that are essential when it comes to making R and D decisions.
  • Six of the top ten pharmaceutical companies in the world use CytoReason’s technology to make data-driven decisions in the therapeutic areas of metabolism, immunology, inflammation, and immuno-oncology.

Israel-based AI disease model startup CytoReason Ltd. raised USD 80 million in a funding round that involved the participation of Nvidia Corp. The company aims to leverage capital to augment its clinical and molecular data, source its models for the latest applications, and commence a new office in the United States this year.

CytoReason was established in 2016 and creates AI-driven disease models to shed light on medical conditions and potential therapies. Scientists and executives can judge drug portfolios and performance by utilizing the company’s platform, which enables treatment comparisons, drug program priority, and real-time updates.

Its main selling point is a proposal to shorten the time spent on research and development. Additionally, it seeks to increase the likelihood of technical and regulatory success for businesses engaged in the life sciences, including those conducting research, developing, and marketing pharmaceuticals, biotechnology products, and medical devices. The platform from CytoReason places a high value on accuracy, speed, and safety—all factors that are essential when it comes to making R and D decisions.

The company offers molecular-level insights and AI tools to therapeutic area leaders, who are experts in their respective domains and drive research and development initiatives, clinical practices, and treatment approaches. These tools help leaders make data-driven decisions. Additionally, the technologies increase the likelihood of successful drug tests.

Technology and scientific advances made possible by CytoReason’s platform have been routinely published in prestigious journals like Nature, Cell, and Gut. In 2023, scientists of CytoReason published 20 articles reviewed by peers across 16 journals, showcasing the scientific yield of the team and technology of the company.

Six of the top ten pharmaceutical companies in the world use CytoReason’s technology to make data-driven decisions in the therapeutic areas of metabolism, immunology, inflammation, and immuno-oncology.

Pfizer Inc. is one of those pharmaceutical businesses that participated in the venture capital round alongside Nvidia, OurCrowd Ltd., and Thermo Fisher Scientific Inc. Additionally, Pfizer and CytoReason have been cooperating since Pfizer invested USD 20 million in the company back in 2022.

Mikael Dolsten, Chief Scientific Officer and President of worldwide research, development, and medical at Pfizer, said, “The rapid expansion of new technologies, like artificial intelligence, holds tremendous potential to help transform what is possible in human health. Our collaboration with CytoReason leverages its cutting-edge immunology multiomics platform to augment Pfizer’s own R and D capabilities and generate invaluable insights into new drug development pathways for patients.”

It should be no surprise that Nvidia is interested in CytoReason, given that the company uses Nvidia AI chips.

Kimberly Powell, Vice President and General Manager of healthcare at Nvidia, stated, “Over the last year, CytoReason has strengthened its platforms using Nvidia’s latest accelerated computing and AI platforms, achieving more than 10x acceleration for inference workloads. Our continued collaboration with CytoReason will help enable more life sciences companies to benefit from CytoReason’s predictive clinical insights.”

With this latest round of funding, CytoReason has now raised about USD 180 million.